| Document |
Document Title |
|
WO/2008/120093A1 |
The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions con...
|
|
WO/2008/112674A1 |
The invention provides compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cannabinoid Receptor 1 (...
|
|
WO/2008/102908A1 |
Disclosed is a novel herbicide. Specifically disclosed is a haloalkylsulfonanilide derivative represented by the general formula (1) below, or an agrochemically acceptable salt thereof. (In the formula, Q represents -N(R5)SO2R6, wherein ...
|
|
WO/2008/079371A1 |
Provided are compounds that are modulators of C3a receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, the compounds are pyridones. In certain embodiments,...
|
|
WO/2008/075006A1 |
The invention provides compounds of formula (I), wherein R1, R2, R3, R4, R5, R6, g, h and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharma...
|
|
WO/2008/073956A2 |
The present invention is directed to cyclic sulfonamide derivatives of formula (I): or a pharmaceutically acceptable salt thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their u...
|
|
WO/2008/066097A1 |
[PROBLEMS] To provide a compound which is usable as a drug, in particular, an insulin secretagogue or a preventive or remedy for a disease in which GPR40 participates such as diabetes or the like. [MEANS FOR SOLVING PROBLEMS] It is found...
|
|
WO/2008/062740A1 |
Disclosed is a compound which has an inhibitory effect on URAT1 activity and is effective for the treatment or prevention of a disease associated with a high serum uric acid level such as hyperuricemia, gouty tophus, acute gouty arthriti...
|
|
WO/2008/053863A1 |
The object is to synthesize a novel compound having a 1,4-benzothiazin-3-one skeleton or a 3,4-dihydroquinolin-2-one skeleton and find a pharmacological activity of the compound. Specifically provided is a compound represented by the for...
|
|
WO2008006979B1 |
Process for preparing compounds of the diaminophenothiazinium type comprising a step for purification of derivatives (II). The products resulting from this process have a high degree of purity. Use of these compounds for the preparation ...
|
|
WO/2008/047655A1 |
Disclosed is a novel substance which has excellent solubility and stability in an aqueous solution corresponding to a biological liquid sample and can be suitably used as a clinical reagent for quantifying hydrogen peroxide in the presen...
|
|
WO/2008/044095A1 |
The novel positively charged pro-drugs of oxicams and related compounds in the general formula (1) 'Structure 1' were designed and synthesized. The positively charged amino groups of these pro-drugs not only largely increases the solubil...
|
|
WO/2008/022938A1 |
The present invention relates to compounds of the general Formula (I) wherein (A) is a 5 or 6-membered aromatic or heteroaromatic ring; R1 is cycloalkyl or is aryl or heteroaryl, wherein at least one ring is aromatic in nature, unsubstit...
|
|
WO/2008/007780A1 |
Disclosed is a pentadienamide derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof or the like. (I) wherein R1 represents a substituted or unsubstituted aryl or a substituted or unsubstituted aromatic h...
|
|
WO/2008/007074A2 |
This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesis and/or purification of certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as "diaminop...
|
|
WO/2008/005451A2 |
An optical apparatus (fig. 1) for producing light of a predetermined intensity from light sources of less than the predetermined intensity includes a first light source; a second light source; a double dove anti-Gaussian generator in opt...
|
|
WO/2007/144769A2 |
A compound of formula (I) wherein: • A represents a phenyl, a heteroaryl or a (C4-C8)cycloalkyl group, • Q represents an oxygen atom or a -CH2- link, • X, Y and Z represent carbon or nitrogen atoms, • R1 and R2 are chosen among: ...
|
|
WO/2007/138998A1 |
Disclosed is a pharmaceutical composition which is effective for the treatment or prevention of a disease associated with uric acid, such as hyperuricemia, tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary cal...
|
|
WO/2007/138242A1 |
Compounds of formula (I) are found to be active against HCV. wherein: R1 is a moiety -A1-L1-A1', -A1-L1-A1'-A1" or -A1-L1-A1'-Y1-A1"; A and B are the same or different and each represent a direct bond or a -CO- NR'-, -NR'-CO-, -NR'-CO-NR...
|
|
WO/2007/139002A1 |
It is intended to provide a method for producing an excellent compound effective in the treatment, prevention or the like of pathological conditions associated with uric acid such as hyperuricemia, tophus, acute gouty arthritis, chronic ...
|
|
WO/2007/133800A2 |
Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 or TLR7 receptors, Trif or of IL-10 or IL-12 inhibits ocular angiogenesis. Fur...
|
|
WO/2007/123516A1 |
The invention is directed to compounds of Formula II: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein t...
|
|
WO/2007/120638A2 |
The invention relates to methods and products for modulating glycosylation of proteins. The invention is useful for treating glycosylation-associated disorders such as neurodegeneration, diabetes, including complications of diabetes such...
|
|
WO/2007/110627A2 |
This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following fo...
|
|
WO/2007/101007A2 |
Compounds of Formula (I) are provided in which the variables are as described herein. Such compounds may be used to modulate bradykinin receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions res...
|
|
WO/2007/093507A1 |
The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R1, R2, R3, R4, R5, R6, V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters the...
|
|
WO/2007/089034A1 |
The present invention relates to a compound, useful as a mineralocorticoid receptor-modulating agent, of the following formula [I]: wherein Ring A is a benzene ring optionally having a substituent(s) other than R1 etc, R1 is a group of t...
|
|
WO/2007/086504A1 |
Disclosed is an excellent inhibitor of URAT1 activity, which is effective for the treatment of a disease associated with uric acid such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty nephropathy, ur...
|
|
WO/2007/082208A2 |
The present invention provides compositions comprising lanthionine ketimine derivatives and thiomorpholine dicarboxylic acid derivatives, as well as processes for the preparation of such compounds. The invention also concerns the use of ...
|
|
WO/2007/070760A2 |
Compounds are provided which bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein, R1, R2, A, Y, X, Ar1 and Ar2 have the meanings given in the specification, ...
|
|
WO/2007/063925A1 |
Disclosed is a novel and excellent therapeutic or prophylactic agent for nociceptive pain, neuropathic pain, cancer pain, headache, bladder dysfunction or the like, which relies on a preventive activity on capsaicin receptor VR1 activati...
|
|
WO/2007/050425A2 |
A compound of formula I,wherein A, X, q, R1, R2a, R2b, R2c, R3a, and R3b are defined herein, useful as liver X receptor modulator.
|
|
WO/2007/049532A1 |
A BACE 1 inhibitor containing, as an active ingredient, any one of a compound represented by the formula (I): (wherein ring A is an optionally substituted carbocyclic group or optionally substituted heterocyclic group; E is lower alkylen...
|
|
WO/2007/045761A1 |
The invention concerns amidine derivatives of general formula (I) exhibiting an inhibitory activity of calpains and/or a trapping activity of reactive forms of oxygen.
|
|
WO/2007/031791A1 |
A compound which is a biphenyl derivative of formula (I), or a pharmaceutically acceptable salt thereof wherein: R1 is a C1-C6 alkyl group or a moiety -A1, -L1-A1, -A1-A1′, -L1-A1-A1′, -A1-L1-A1′, -A1-Y1-A1′, -A1-Het1-A1′, -L1-...
|
|
WO/2007/033266A2 |
Pharmaceutical compositions comprising 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-
dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and pharmaceutically acceptable salts thereof are provided as well as kits and articles of m...
|
|
WO/2007/020932A1 |
A method of manufacturing an organic silicon compound that contains a methacryloxy group or an acryloxy group, the method being characterized by the fact that manufacturing or conducting purification by distillation is carried out in the...
|
|
WO/2007/020954A1 |
Disclosed is a polymer compound containing a residue of a compound represented by the following formula (1). (In the formula, ring C1, ring C2 and ring C3 independently represent an aromatic hydrocarbon ring or a heterocyclic ring; A1 re...
|
|
WO/2006/134955A1 |
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...
|
|
WO/2006/129609A1 |
The object is to prepare a 2-naphthylimino-5,5-disubstituted-1,3-thiazin derivative and a pharmaceutical composition comprising the compound as an active ingredient and to provide an analgesic agent, a therapeutic agent for pain, an anti...
|
|
WO/2006/117743A1 |
The present invention relates to substituted aromatic compounds, which have PPAR modulating activity, and hence can be used as anti-diabetic agents. Compounds described herein can be used as peroxisome proliferation activated receptor (P...
|
|
WO/2006/113650A1 |
A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6n and 7d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell ...
|
|
WO/2006/110221A1 |
Various non-limiting embodiments disclosed herein relate to photochromic materials having extended pi-conjugated systems. For example, various non-limiting embodiments disclosed herein provide a photochromic material, such as an indeno-f...
|
|
WO/2006/105289A1 |
Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.
|
|
WO/2006/093339A1 |
A composition for inhibiting the extracellular matrix gene transcription comprising a cinnamoyl compound represented by the formula (I) and an inert carrier, or the like.
|
|
WO/2006/082495A1 |
The present invention relates to novel acetic acid derivatives as peroxisome proliferator activated receptor (PPAR) modulators. Compounds described herein can be useful to inhibit or prevent diabetes or diabetes associated complications ...
|
|
WO/2006/079720A1 |
The invention concerns compounds of formula (I) and their use as hypoglycaemic or hypolipidemic agents
|
|
WO/2006/057460A1 |
An URAT1 activity inhibitor which contains a nitrogen-containing fused ring compound represented by the following general formula [1]: [1] wherein each symbol is as defined in the description. This URAT1 activity inhibitor is useful in, ...
|
|
WO/2006/050830A1 |
The invention relates to substituted benzoylguanidines of formula (I), where R1 to R8, X and Y have the meanings given in the claims and the pharmaceutically-acceptable salts thereof which are substituted acylguanidines and inhibit cellu...
|
|
WO/2006/050054A2 |
Benzolactam boronic acid compounds and pharmaceutical formulations are described along with methods of use thereof for inhibiting inflammatory cytokines such as tumor necrosis factor alpha (TNF-&agr ) in a subject in need thereof.
|
